Zacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by Analysts

Shares of Celyad SA (NASDAQ:CYAD) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $74.00 for the company, according to Zacks. Zacks has also given Celyad an industry rank of 196 out of 265 based on the ratings given to related companies.

Several equities research analysts have recently issued reports on the stock. Piper Jaffray Companies reissued an “overweight” rating and set a $74.00 target price on shares of Celyad in a research note on Monday, October 9th. ValuEngine lowered shares of Celyad from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.

Shares of Celyad (CYAD) opened at $45.80 on Monday. Celyad has a 12-month low of $19.57 and a 12-month high of $64.75.

ILLEGAL ACTIVITY WARNING: “Zacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by Analysts” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at

Celyad Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Get a free copy of the Zacks research report on Celyad (CYAD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with's FREE daily email newsletter.

Leave a Reply